Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction.
暂无分享,去创建一个
B. Pitt | F. Zannad | P. Rossignol | T. Thum | N. Girerd | J. Ferreira | C. Bär | S. Stienen | A. Barros | Susan Stienen
[1] J. Cleland,et al. Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure , 2020, European journal of heart failure.
[2] P. Wołkow,et al. Relations between circulating and myocardial fibrosis-linked microRNAs with left ventricular reverse remodeling in dilated cardiomyopathy. , 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[3] B. Pitt,et al. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without , 2019, Clinical Research in Cardiology.
[4] Arantxa González,et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. , 2015, Journal of the American College of Cardiology.
[5] Thomas Thum,et al. Noncoding RNAs and myocardial fibrosis , 2014, Nature Reviews Cardiology.
[6] Gianpaolo Zerbini,et al. MiR‐133a regulates collagen 1A1: Potential role of miR‐133a in myocardial fibrosis in angiotensin II‐dependent hypertension , 2012, Journal of cellular physiology.
[7] J. Bauersachs,et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.
[8] B. Pitt,et al. Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study , 2009, Circulation.
[9] B. Pitt,et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .